SkinBioTherapeutics PLC SkinBiotix technology successful in stability test (4866Z)

TIDMSBTX

RNS Number : 4866Z

SkinBioTherapeutics PLC

03 September 2018

SkinBioTherapeutics plc

SkinBiotix(R) technology successful in stability testing

Manchester, UK - 3 September 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to provide an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.

Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:

"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month."

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

 
 SkinBioTherapeutics plc                      Tel: [phone] 
  Dr. Cath O'Neill, CEO                        2760 
  Doug Quinn, CFO 
 Cairn Financial Advisers LLP (Nominated      Tel: [phone] 
  Adviser)                                     0880 
  Tony Rawlinson / Sandy Jamieson / Richard 
  Nash 
 Turner Pope Investments (Joint Broker)       Tel: [phone] 
  Ben Turner / James Pope                      4120 
 
  Northland Capital Partners (Joint Broker) 
  Tom Price                                    Tel: [phone] 
                                               6625 
 Instinctif Partners (Media Relations)        Tel: [phone] 
  Melanie Toyne-Sewell / Deborah Bell          2020 
                                               [e-mail] 
 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDEAPPFDAPPEFF

(END) Dow Jones Newswires

September 03, 2018 02:00 ET (06:00 GMT)